Results 181 to 190 of about 28,496 (220)
Some of the next articles are maybe not open access.
Thrombosis in Myeloproliferative Neoplasms
Seminars in Thrombosis and Hemostasis, 2014Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and it involves various abnormalities of
Falanga, A, Marchetti, M
openaire +3 more sources
Pediatric Myeloproliferative Neoplasms
Clinics in Laboratory Medicine, 2021Myeloproliferative neoplasms can present early in life and may present a diagnostic challenge. Very few studies have focused on the diagnosis, prognosis, and therapy for pediatric myeloproliferative neoplasms. This article focuses on chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis in children.
Farah, El-Sharkawy +1 more
openaire +2 more sources
Myeloproliferative Neoplasms with Monocytosis
Current Hematologic Malignancy Reports, 2021Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) resulting in constitutive activation of JAK/STAT and other signaling pathways.
Erika Morsia, Naseema Gangat
openaire +2 more sources
Inflammation and myeloproliferative neoplasms
Journal of Autoimmunity, 2017Myeloproliferative neoplasms (MPN) include three main entities: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF). MPN represent a unique model of the relationship between the clonal development of a hematologic malignancy and chronic inflammation.
F. Lussana, A. Rambaldi
openaire +2 more sources
Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms
Advances in Anatomic PathologyThe International Consensus Classification (ICC) updated in 2022 the World Health Organization (WHO) classification of hematopoietic tumors (2016 revision of the 4th edition WHO classification). Although the major categories of myeloid neoplasms remained unchanged from the prior WHO classification, many disease entities including those in the ...
Sonam Prakash, Attilio Orazi
openaire +2 more sources
Genetics of the myeloproliferative neoplasms
Current Opinion in Hematology, 2011Since the discovery of the JAK2V617F mutation in 2005, an increasing number of somatic and germline genetic events responsible for myeloproliferative neoplasm (MPN) pathogenesis have been uncovered. The purpose of this review is to outline the most recent discoveries of the genetic alterations found in patients with MPNs.In addition to the JAK2V617F ...
openaire +2 more sources
2021
In the 2017 WHO classification, chronic myeloid neoplasms include myeloproliferative neoplasms (MPNs), myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), myelodysplastic syndrome (MDS), mastocytosis and myeloid/lymphoid neoplasms with eosinophilia with rearrangements in FGFR1, PDGFRA, PDGFRB, or PCM1-JAK2 fusions.
Julie Li, Gang Zheng
openaire +1 more source
In the 2017 WHO classification, chronic myeloid neoplasms include myeloproliferative neoplasms (MPNs), myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), myelodysplastic syndrome (MDS), mastocytosis and myeloid/lymphoid neoplasms with eosinophilia with rearrangements in FGFR1, PDGFRA, PDGFRB, or PCM1-JAK2 fusions.
Julie Li, Gang Zheng
openaire +1 more source
Cytogenetics of Myeloproliferative Neoplasms
2011The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid
openaire +2 more sources